Coexpression of tumor antigens together with immunomodulatory molecules is a strategy in DNA vaccination aiming at an amplification of the antitumor immune response. Epstein-Barr virus-induced-molecule-1-ligand-chemokine (ELC/CCL19) is a CC chemokine that binds to the chemokine receptor CCR7. CCR7 is expressed on mature dendritic cells (DC) and distinct T-and B-cell subpopulations. CCL19 (ELC) is mainly expressed in secondary lymphoid organs and plays a central role in regulating the encounters between DC and T cells. We asked whether CCL19 is able to augment immunogenicity of a DNA vaccine in a C57BL/6 mouse model with syngeneic MCA205 (b-gal) tumor cells. Mice were vaccinated twice intramuscularly on days 1 and 15 and tumor challenge was performed subcutaneously on day 25. Coadministration of plasmid DNA (pDNA) (b-gal) plus pDNA (CCL19) was compared with pDNA (b-gal), pDNA (CCL19), mock vector and phosphate-buffered saline (PBS) alone. Coexpression of CCL19 resulted in enhancement of a Th1-polarized immune response with substantial improvement of the protective effect of the DNA vaccine. Immunohistochemical staining revealed an increased CD8 þ T-cell infiltration in the tumor tissue of mice that had been immunized with pDNA (b-gal) plus pDNA (CCL19). We conclude that CCL19 is an attractive adjuvant for DNA vaccination able to augment antitumor immunity and that this effect is partially caused by enhanced CD8 þ T-cell recruitment.
Introduction
Genetic immunization using naked DNA is an attractive approach for tumor vaccination. There is evidence from different animal models that in vivo transfection of dendritic cells (DC) plays a crucial role in inducing immunity after injection of plasmid DNA (pDNA) coding for tumor antigens. [1] [2] [3] DNA vaccines combine the most desirable attributes under the aspect of clinical application against cancer: they (1) code for multiple major histocompatibility complex (MHC) class I-and class IIrestricted epitopes, which may be presented to both CD4 þ and CD8 þ T cells, (2) lead to a preferential MHC class-I expression of the antigen, (3) contain CpGrich sequences that are strongly immunogenic, (4) can be produced as a 'general' vaccine being applicable to any individual and (5) are not afflicted with safety concerns like viral vectors. [1] [2] [3] Despite induction of both cellular and humoral immune responses by DNA vaccines, application against cancer has been hampered in many cases by the failure of the vaccine to induce tumor rejection. Therefore, in the past there have been several efforts to augment immunogenicity of DNA vaccines, most of them aiming at one of the following strategies: (1) coexpression of immunomodulatory molecules such as cytokines, co-stimulatory molecules or chemokines, 4 (2) enhancing DC-directed antigen uptake and (3) amplification of DC recruitment at the site of antigen expression, that is, by administration of Flt-3L. 5, 6 Recent studies have indicated that the chemokine receptor CCR7 and its CC chemokine ligands EpsteinBarr-virus-induced-molecule-1-ligand-chemokine (ELC/ CCL19) and secondary lymphoid organ chemokine (SLC/CCL21) play a central role in directing DC and T cells into lymphoid tissue where T-cell priming and reactivation take place. CCL19 and CCL21 are constitutively expressed by cells distributed throughout the T-cell zones of lymph nodes, spleen and Peyer's patches. CCL21 is additionally expressed in high endothelial venules (HEV) in lymph nodes and Peyer's patches and by lymphatic endothelial cells. [7] [8] [9] [10] [11] [12] Both cytokines have substantial impact on the evolution of primary and secondary immune responses.
We asked whether coexpression of CCL19 together with antigen is able to amplify protective antitumor immunity in a tumor challenge mouse model with bgalactosidase (b-gal) as antigen.
Material and methods

Animals
Female 8-12-weeks-old C57BL/6 (H-2k b ) mice were purchased from Charles River (Wilmington, MA, USA) and maintained in our animal facility under standard conditions.
Experiments were approved by local authorities (LAGeTSi, Berlin, Germany) who supervise animal studies.
Cell lines
MCA 205 is a methylcholantrene-induced fibrosarcoma, EL-4 is a lymphoma. Both cell lines are syngeneic to C57BL/6 mice and were cultured in Roswell Park Memorial Institute medium (RPMI) 1640 supplemented with 10% fetal calf serum (FCS), nonessential amino acids (Gibco, Invitrogen, Karlsruhe, Germany), 50 mM 2-mercaptoethanol and penicillin/streptomycin (100 IU/ml, 100 mg/ml)(Gibco). MCA 205 cells that had been retrovirally transduced with the LacZ gene were kindly provided by S Cayeux and Th Blankenstein (MDC, Berlin, Germany). Retroviral transduction was performed as described previously. 13 In the MCA 205 (b-gal) cells used in our experiments, the percentage of b-gal expression was always 495%.
Preparation of plasmid DNA Mock vector (pcDNA3), pDNA (b-gal) containing the LacZ gene, coding for b-galactosidase, under the control of a cytomegalovirus promoter and pDNA (CCL19) coding for hCCL19 were used for vaccination experiments. The plasmids were amplified in Escherichia coli X1-blue strain (Stratagene, La Jolla, CA, USA) and purified using the EndoFree Giga prep kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
Immunization protocol
Mice were injected twice intramuscular with 100 mg pDNA on days 1 and 15. Each treatment group consisted of 5-10 mice. Mice were injected with pDNA (b-gal) plus pDNA (CCL19),pDNA (b-gal), pDNA (CCL19), mock vector or phosphate-buffered saline (PBS). Progressively growing masses 41 mm mean diameters were regarded as tumors. Tumor diameters were measured 1-2times weekly by calipers in accordance with the German animal protection law. Tumor volumes were calculated as follows: tumor volume ¼ 1/6pd 3 , where d is the diameter. For in vitro immunological assays, surviving mice from the different groups that had completely rejected the tumor were boosted in week 24. One week later, animals were killed and splenocytes were used for the different immunological assays (Figure 1 ).
Preparation of splenocytes
Spleens were aseptically removed and a single-cell suspension was generated in RPMI-1640 (Gibco) supplemented with 100 IU/ml penicillin, 100 mg/ml streptomycin (Gibco), 2 mM L-glutamine (Gibco), 50 mM 2-mercaptoethanol (Gibco) and 10% FCS (Gibco) (complete medium). Erythrocytes were lysed by using erythrocyte lysis buffer (ethylenediaminetetraacetic acid-NH 4 Cl þ Na 2 CO 3 ). Finally, splenocytes were washed twice in RPMI-1640 and subsequently used for immunological assays.
Phenotypical analysis of DC and T cells by flow cytometry Direct immunofluorescence cell staining was performed using the following antibodies: CD11c-PE, CD44-PE, CD40-FITC, CD80-FITC, CD86-FITC, CD11b-FITC, A-Ib-FITC, CD3-FITC, CD4-PerCP, CD8-PerCP and CD62L-APC (all from Pharmingen, Heidelberg, Germany). A total of 10 000 cells were analyzed using a FACScan (Becton & Dickinson, Mountain View, CA, USA).
Immunohistochemistry
Samples from spleen, regional lymph nodes or local injection site of mice were placed in embedding medium (Tissue Tek OTC compound, SAKURA, Giessen, Germany), snap-frozen in liquid nitrogen, and stored at À801C. From these frozen samples cryostat sections were prepared and fixed in acetone. Cryostat sections were incubated subsequently with (1) blocking buffer (PBS containing 3% bovine serum albumin, Sigma, Taufkirchen, Germany) (2) Proliferative T-cell responses About 6-9wells with 10 5 splenocytes were cultured in complete medium with or without 5 mg/ml of b-gal protein (Roche Applied Science) using 96-well round-bottom plates (Nunc, Life Technology GmbH, Karlsruhe, Germany). On day 3, 3H-thymidine (1 mCi/well) was added. Cells were harvested and 3H-thymidine incorporation was measured using a Top Count (Packard Bio Science, USA), 18-20 h later.
ELISpot assay
For ELISpot assays splenocytes were seeded into 4-6 wells (10 6 splenocytes/well) on a g-interferon-or IL-4 ELISpot plate (ELISpot Kit, Pharmingen, Heidelberg, Germany). Peptides were added at a concentration of 1 mg/ml. Incubation was performed overnight and ELISpot plates were developed according to the manufacturers' instructions. Evaluation was performed by means of an AID ELISpot reader system (AID, Strassberg, Germany). Peptide-specific responses were defined as having (1) a ratio of specific peptide/control X2 and (2) an absolute number of spots 410. Results were expressed as 'spots per 10 6 splenocytes'.
Chromium release assay
Splenocytes were re-stimulated in vitro for 5 days in complete medium in the presence of 5 mg/ml b-gal peptide (DAPIYTNV, Wita GmbH, Berlin, Germany), 2.5-5 U/ ml IL-2 and 10 U/ml IL-7 (Peprotech, London, UK). Immunogenicity of the K b -restricted peptide DAPIYTNV in the C57BL/6 mouse model is well established. 14 Additional experiments were performed using recombinant b-gal protein (Roche Applied Science, Mannheim, Germany) or irradiated MCA (b-gal) cells for in vitro restimulation. The cell line EL-4 pulsed with 10 mg/ml b-gal peptide and labeled with 51 Cr was used as target. On day 5, effector and target cells were co-incubated for 4.5 h at 371C. After that time, 50 ml of culture supernatant was transferred into lumina plates (Packard) and evaluated by a counter (Top Count, Packard Bio Science, USA). The percent specific cytotoxicity was calculated using the formula: % specific cytotoxicity ¼ 100(experimental release-spontaneous release)/maximum release-spontaneous release).
Cytometric bead array
Cytometric bead array assays (CBA) permit simultaneous cytometric quantitation of multiple cytokines in solution by capturing these to spectrally distinct beads. The cytokine pattern measured by the CBA used (CBA, Becton & Dickinson, Heidelberg, Germany) consists of interferon-g (INF-g), interleukin (IL)-2, tumor necrosis factor (TNF)-a, IL-4, IL-10 and IL-5. For CBA, cell culture supernatants were frozen at À801C until cytokine analysis was performed according to the manufacturer's instructions.
A peptide-specific response was defined as having a ratio cytokine secretion of specific peptide/cytokine secretion of control peptide X2.
Enzyme-linked immunosorbent assay
Antibody responses were analyzed in serum samples by enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well microtiter plates (Nunc Immuno MaxiSorp plates, Life Technology GmbH, Karlsruhe, Germany) were coated overnight at 41C with 100 ml of a solution containing 1 mg/ml b-gal (Roche Applied Science) in PBS, pH 7.4. Plates were washed once with washing buffer TPBS (PBS þ 0.05% Tween 20 ) and then treated overnight with 250 ml of blocking buffer (0.5% BSA, fraction V, Roth, in washing buffer þ 0.1% sodium acid). After washing twice, plates were incubated at room temperature (RT) for 1 h with 100 ml of serial dilutions of serum samples in TPBS (1:30, 1:60, 1:120 and 1:240). After washing 4 times with TPBS, plates were incubated for 1 h with 100 ml of a 1:1000 dilution of biotinylated anti-mouse IgG1, IgG2a, IgG2b, IgG3 (Pharmingen, Heidelberg, Germany) in TPBS. Hereafter, plates were washed four times with TPBS and incubated with 100 ml of a 1:1000 dilution of streptavidin-alkaline phosphatase (AKP) (Pharmingen, Heidelberg, Germany). After 0.5-1 h incubation at RT, plates were thoroughly washed and 200 ml 4-MethylUmbelliferyl Phosphate (4-MUP) (Sigma) was added in each well. After 0.5-1 h at RT, photometric analysis was performed using a photometer (Multilabel Counter, Wallac).
Statistical methods
For comparison of the means of three or more groups, analysis of variance (ANOVA) was used together with PRISM software. Student's t-test was used to compare the means between two groups. Differences were considered significant when Po0.05.
Results
CCL19 mediates protection from tumor growth in C57BL/6 mice challenged with syngeneic b-galtransfected MCA205 tumor cells The efficacy of CCL19 as an adjuvant for DNA vaccination was evaluated in C57BL/6 mice that were immunized twice (d1 and d15) with a combination of pDNA (b-gal) plus pDNA (CCL19), pDNA (b-gal), pDNA (CCL19), mock vector or PBS. After two intramuscular immunizations on days 1 and 15 and subcutaneous challenge with MCA205 (b-gal) tumor cells on day 25, a substantial proportion (60%) of the mice coinjected with pDNA (b-gal) plus pDNA (CCL19) remained tumor-free during the first 4 weeks. In the control groups, the percentage of tumor-free mice was 30% (pDNA-b-gal), 25% (pDNA-CCL19), 18% (mock vector) and 5% (PBS) (Figure 2a ). Between weeks 6 and 23 a part of the initially tumor-free mice immunized with pDNA (b-gal) plus pDNA (CCL19) developed tumors; however, in 38% of the mice long-term tumor-free survival was observed. In the control animals immunized with pDNA (b-gal) or pDNA (CCL19) long-term tumorfree survival was only approximately 20%, whereas vaccination with mock vector or PBS did not induce long-term protection from tumor growth (Figure 2b ). The improvement of short-and long-term survival observed in mice that had been immunized with pDNA (b-gal) plus pDNA (CCL19) was statistically significant (Po0.05).
When comparing the tumor growth curve slopes in the different groups of mice, there was a significant retardation in tumor growth induced by immunization with pDNA (b-gal) plus pDNA (CCL19). In fact, until day 30 there was nearly a complete inhibition of tumor growth in the pDNA (b-gal) plus pDNA (CCL19) group compared with the control mice. Whereas mice injected with PBS or mock vector showed a rapid increase of the tumor size, tumor growth was substantially slower in mice immunized with pDNA (b-gal) or pDNA (CCL19) and it was completely suppressed in mice that had been co-injected with pDNA (b-gal) plus pDNA (CCL19) (Po0.05) (Figure 3) . These results not only show that pDNA (CCL19) can serve as an adjuvant for DNA vaccination they also demonstrate that pDNA (CCL19) alone is able to convey some protection from tumor growth.
CCL19 increases the proliferative immune response in C57BL/6 mice challenged with syngeneic b-gal-transfected MCA205 tumor cells Vaccination efficacy after injection of pDNA (b-gal) plus pDNA (CCL19), pDNA (b-gal), mock vector or PBS was compared by using splenocytes of immunized mice and controls in a standard 3H-thymidine proliferation assay with b-gal as an antigen (Figure 4) . Vaccination was performed according to the schedule shown in Figure 1 . Surviving mice were boosted in week 24. One week thereafter, mice were killed to perform proliferation assays with splenocytes from the different groups of mice. b-gal protein was used as antigen. Mice immunized with pDNA (b-gal) alone had a weak but significant antigen-specific proliferative response against b-gal (stimulation index approximately 2, Po0.05). Figure 4 shows that coadministration of pDNA (CCL19) during DNA vaccination leads to an increase of the b-gal-specific proliferative response. In our experiments, the proliferative response was increased by a factor 2.4 compared with pDNA (b-gal) alone (Po0.05). pDNA (CCL19) alone could also increase b-gal-specific in vitro proliferation; however, this increase was not statistically significant when compared with pDNA CCL19 induces a TH1 polarized T-cell response in C57BL/6 mice challenged with syngeneic b-gal-transfected MCA205 tumor cells Induction of b-gal-specific T-cell immunity was studied by standard g-interferon-and IL-4-ELISpot as well as by CBA in splenocytes from mice, which had remained tumor-free after immunization and subsequent tumor challenge. In week 24 these mice were boosted with pDNA (b-gal), T-cell assays were performed 1 week later.
In the pDNA (b-gal) plus pDNA (CCL19) group there was a strong induction of b-gal-specific g-interferonsecreting T cells as compared with mice that had only received pDNA (b-gal). IL-4-ELISpot did not detect b-gal-specific T cells suggesting a TH1-type of T-cell response (Figure 5a and b) . pDNA (CCL19 ) alone did not induce a significant antigen-specific TH1 T cell as compared with PBS by means of a g-interferon ELISpot assay (Figure 5c ).
Comparison of the cytokine secretion profile of splenocytes from surviving mice that had been immunized with pDNA (b-gal) plus pDNA (CCL19) or pDNA (bgal) alone was performed by CBA 1 week after a boost with pDNA (b-gal). Splenocytes from immunized mice were re-stimulated in vitro in the presence of IL-2, IL-7 and b-gal peptide for 5 days. Supernatant from these T-cell cultures was analyzed by CBA. In these experiments, mice from the pDNA (b-gal) plus pDNA (CCL19) group clearly showed amplification of a TH1-type cytokine secretion profile as compared with mice that had been vaccinated with pDNA (b-gal) alone. In the CCL19 group peptide-induced secretion of the TH1-cytokine g-interferon (and to a less extent, IL-2 and TNF-a) were increased, whereas IL-4-and IL-5-production (representing TH2-cytokines) was very low (g-interferon: 866 vs 194 pg/ml, TNF-a: 90 vs 63 pg/ml, IL-2: 16.6 vs 11.8 pg/ml, IL-4: 15.5 vs 15.8 pg/ml, IL-5: 28.2 vs 30.2 pg/ml).
Cytotoxic activity of splenocytes from immunized mice was analyzed in animals that had remained tumor-free after tumor challenge. These mice had been immunized twice with DNA coding for CCL19 plus b-gal (group 1), b-gal (group 2) or PBS (group 3) according to the schedule depicted in Figure 1 ; in week 24 they were boosted with pDNA (b-gal). One week later, splenocytes from the three different groups were re-stimulated in vitro for 5 days with antigen (b-gal peptide, b-gal protein or MCA-b-gal cells) in the presence of IL-2 and IL-7. In several experiments, there was rather a low level of specific cytotoxicity with no difference between groups 1 and 2 (specific cytotoxicity: group 1: 17, group 2: 18, group 3: 6%) (data not shown).
CCL19 amplifies a TH1-type humoral immune response in C57BL/6 mice challenged with syngeneic b-gal-transfected MCA205 tumor cells Humoral immune response was also analyzed in animals that had remained tumor-free after tumor challenge. In the pDNA (b-gal) plus pDNA (CCL19) group there was a higher level of anti-b-gal antibodies as compared with the pDNA (b-gal) group. In particular, there was a strong increase of antibodies of the IgG2a subclass, which fits nicely with a TH1-type of immune response ( Figure 6 ).
Analysis of immune effector cells in spleen, regional lymph nodes, tumor tissue and in splenocyte cultures from C57BL/6 mice challenged with syngeneic b-gal-transfected MCA205 tumor cells After having established an amplification of a TH1 T-cell response by coexpression of CCL19 in our experimental mouse model, we asked for the immunological mechanism by which CCL19 exerts its influence on the emerging immune response. First, splenocytes from immunized mice were analyzed for the composition of different immune effector cells (CD8 þ and CD4 þ T cells, DC, B cells and NK cells). A significant difference between mice coinjected with pDNA (CCL19) and those which were not, could not be found (data not shown). However, after 5 days in vitro restimulation in the presence of b-gal-peptide and IL-7/ IL-2, splenocyte cultures from CCL19-treated mice which had survived tumor challenge contained more T cells, in particular CD8 þ T cells than splenocytes from mice which were immunized with pDNA (b-gal) alone. T-cell number was increased approximately by a factor 2.6 for CD8 þ T cells (23.3 vs 9%) and a factor 1.4 for CD4 þ T cells (37.6 vs 26.8%). Flow cytometric analysis of the phenotype of these T cells revealed that they contained T cells with an effector (CD62L-, CD44 þ ), memory (CD62L þ , CD44 þ ) and naive (CD62L þ , CD44-) phenotype (data not shown). Immunohistochemical analysis of cryosections and flow cytometric analysis from spleen and regional lymph nodes did not show any significant difference between the different groups of immunized mice: neither for T cells nor DC, B cells or NK cells (data not shown). However, in tumor tissue of mice immunized with pDNA (b-gal) plus pDNA (CCL19) we detected a much higher number of CD8 þ T cells as compared with mice that were injected with pDNA (b-gal), pDNA (CCL19) or PBS alone (Figure 7a ). For CD4 þ T cells there was no quantitative difference between the groups, but immunohistochemical staining showed diffuse infiltration of CD4 þ T cells in the subcapsular region whereas in the other groups of mice CD4 þ T cells seemed to be accumulated in connective tissue surrounding the tumor margins (Figure 7b ).
Discussion
DNA vaccines have the potential for application as a 'general vaccine' against putative tumor antigens across HLA barriers in a large cohort of patients. Therefore, development of new strategies to improve the anti-tumor efficacy of genetic immunization with naked DNA is of high clinical relevance.
Our investigation was focused on the influence of CCL19 as adjuvant rather than evaluation of a particular tumor antigen as vaccine. The b-gal mouse model was chosen for our vaccination studies because it is well established and offers several advantages: b-gal is a reporter gene whose expression can easily be monitored by X-gal staining and a broad spectrum of reagents (MHCrestricted peptides, recombinant protein, anti-b-gal antibodies as well as several DNA vectors) 13, 14 are readily available for detailed studies of anti-b-gal immunity.
In a C57BL/6 mouse model with syngeneic b-galexpressing tumors we were able to demonstrate that the local coexpression of the CC chemokine CCL19 (ELC) is able to induce a TH1-polarized anti-tumor T-cell response leading to (partial) protection from a tumor challenge and significant retardation of tumor growth. Retardation of tumor growth in CCL19-treated mice was most prominent during the initial phase of tumor development until week 10 and declined thereafter. Repetitive vaccinations over a longer time period might possibly boost anti-tumor immunity and result in more prolonged tumor protection. To analyze and to compare the anti-tumor immune response of the different vaccination groups, we chose animals from the different groups that had survived tumor challenge and had remained tumor-free. Particularly in these animals, the detection of possible differences in cellular and humoral immunity was expected as they had achieved complete tumor rejection and long-term survival. CCL19-treated mice developed an increased cellular and humoral antigen-specific immune response with a typical TH1 cytokine profile resulting in tumor rejection in a substantial proportion of animals. Although a CCL19-induced TH1-polarized immune response could Cr-release cytotoxicity assay in splenocytes from CCL19-treated mice did not show any enhancement of cytotoxic activity compared with splenocytes from mice vaccinated with pDNA (b-gal) alone. Given the fact that a CCL19-induced increase of tumor rejection was observed in vivo, there are different possible explanations for this discrepancy: (1) chromium release assay does not necessarily detect all cytotoxic mechanisms displayed by effector cells 15 and in vivo rejection of tumor cells by CD8 þ T cells that kill independently of perforin and FasL have been described, 16 (2) CCL19-induced antitumor effects could be mediated (in part) by cells other than T cells. Finally, weak cytotoxic activity might be inherent to the b-gal mouse model and has previously been described. 6, 17 Enhancement of immunogenicity of DNA vaccines by CCL19 has previously been described for a vaccine against herpes simplex virus 18,19 both for intramuscular and mucosal routes of administration. An increase of humoral as well as cellular immunity against HSV was demonstrated. Furthermore, there have been reports in mice showing that CCL19-transfected tumor cells lead to retardation in tumor growth 20, 21 and that intratumoral/ intranodal injection of recombinant CCL19 elicits IFN-gdependent systemic anti-tumor responses in a mouse lung cancer model. 22, 23 Interestingly, the latter studies describe an increased influx of CD8 þ and CD4 þ T cells as well as DC into tumor sites of CCL19-treated mice.
Despite clear evidence of a Th1-polarized T-cell response and amplification of tumor-protective immunity by CCL19 in our study, there are two issues which could not be fully elucidated: (1) the immunological mechanism which primarily leads to this Th1 T-cell response and (2) the anatomical site where it occurs (most likely injection site or regional lymph nodes). As CCR7, the receptor of CCL19, is expressed both on mature DC and on T-cell subsets (naive T cells and subfraction of central memory T cells), the effect may be DC-mediated, T-cell-mediated or both. DC and T-cell function are interdependent. Mainly for this reason, it is not possible to dissect completely CCL19 effects on DC and T cells in vivo: depletion or functional impairment of one cell type would automatically diminish the function of the other, so that this question cannot be clarified in depletion experiments or knock-out models. On the one hand, there are several studies describing a direct influence of CCL19 on mature DC: CCL19 can induce marked extension of dendrites and rapid endocytosis in mature DC. 24, 25 These data suggest an increase in DC function leading to an enhanced anti-tumor response after administration of pDNA (CCL19) in mice. In our experimental system, the only finding shedding some light on this question is the accumulation of CD8 þ T cells at the tumor site. One possible explanation is an increased recruitment of antigen-specific CD8 þ T cells in mice co-injected with pDNA (b-gal) plus pDNA (CCL19) with subsequent localization to the tumor. This might either be due to quantitative or qualitative improvements of mature DC function and/or due to attraction of higher numbers of naive or central memory T-cells to lymphoid tissue following a high gradient of CCL19 expression. The question where this T-cell recruitment occurs has mainly two possible answers: at the injection site as de novo formation of lymphoid tissue 26, 27 or in regional lymph nodes. We would favor the latter possibility, as on immunohistochemistry at least we did not find signs for priming at the injection site and there are data showing that CCL19 that is injected into the footpads of mice enters regional lymph nodes and is presented by HEV. When injected intracutaneously, CCL19 is able to restore T-cell trafficking to regional lymph nodes in mice lacking functional CCL19 and CCL21. 28 Furthermore, there are data demonstrating that CCL19 is expressed by DC in lymphoid tissues and that it strongly attracts naive T cells. 29, 30, 31 We therefore postulate that after intramuscular DNA injection, it is mainly CCL19 expression occurring in regional lymph nodes (in DC and other cells), which is responsible for increased recruitment of naive T cells and possibly DC. This results in enhanced expansion of antigen-specific T cells, which may migrate to the tumor site and mediate tumor rejection. Additional amplification of DC function could be a part of the immunogenic process. An increase of the encounters between T cells and APC might also explain the immunological effects that were observed after injection of pDNA (CCL19) alone compared with mock vector or PBS. For future DNA vaccine development in cancer research, CCL19 is an attractive adjuvant. This is underlined by a recent study with a DNA vaccine containing a fusion molecule between multiple epitopes from human prostate-specific membrane antigen and another CCR7 ligand, CCL21, which has biological properties that resemble CCL19 in many aspects. In this latter study, colocalization of DC and T cells and induction of CTL were demonstrated, resulting in an enhancement of anti-tumor immunity. 32 Fusion genes between tumor antigens and CCL19 are also an attractive vaccination strategy for the future.
